We are leveraging our RIPTAC platform to build a robust pipeline of oral, precision treatments for many cancer types. The novel hold and kill mechanism of RIPTAC therapeutics has the potential to overcome drug resistance, a common problem with today’s precision oncology therapies. RIPTAC therapeutics kill cancer cells independent of the oncogenic driver of the disease, and our initial drug candidates in the clinic are designed to address the large unmet need of patients with tumors that have developed resistance to existing drugs.
Our most advanced drug programs are for prostate cancer and breast cancer, the two most prevalent solid tumors, which together affect approximately 1 in 8 Americans. For each of these cancers, Halda has designed a RIPTAC therapeutic that leverages a protein expressed at high levels in the tumors, enabling selectivity of the cancer cell-killing mechanism. As oral small molecule medicines, RIPTAC therapeutics can be administered conveniently, including in community cancer centers where many patients with common cancers are initially treated.
Disease Indication
PRECLINICAL
ENABLING
DEVELOPMENT
Metastatic, castration resistant prostate cancer (mCRPC)
Hormone receptor positive (HR+) metastatic breast cancer
Undisclosed
HLD-0915
Metastatic, castration resistant prostate cancer (mCRPC)BREAST CANCER RIPTAC
Hormone receptor positive (HR+) metastatic breast cancerADDITIONAL RIPTACs
Undisclosed
HLD-0915, OUR LEAD DRUG PROGRAM FOR PROSTATE CANCER – RIPTAC THERAPEUTIC LEVERAGING ANDROGEN RECEPTOR EXPRESSION
Our lead drug candidate, HLD-0915, is an orally administered RIPTAC therapeutic with a novel mechanism designed to overcome drug resistance in the treatment of metastatic castration resistant prostate cancer (mCRPC), to be followed by investigation in earlier lines of therapy. Halda has presented preclinical data demonstrating the mechanism of action of this drug against prostate cancer. HLD-0915 simultaneously binds two proteins: the Androgen Receptor (AR) to selectively direct the RIPTAC therapeutic to tumor cells; and an essential cellular protein involved in transcriptional regulation. The resulting trimeric complex results in the abrogation of the essential protein’s function and selective prostate cancer cell death. HLD-0915 demonstrates a selective in vitro killing effect against prostate cancer cell lines, and in vivo antitumor activity in rodent models of prostate cancer. We expect to advance HLD-0915 into a Phase 1 clinical trial in cancer patients in 2025.
OUR RIPTAC DRUG PROGRAM FOR BREAST CANCER
Our next most advanced RIPTAC drug candidate is designed to overcome resistance in the treatment of hormone receptor positive (HR+) metastatic breast cancer. We are currently optimizing the hold and kill mechanism and conducting preclinical studies to evaluate the selective delivery of the RIPTAC therapeutic to these tumors in order to drive cancer cell death.
DATA DRIVES OUR PIPELINE PROGRESS
HALDA
THERAPEUTICS
115 Munson Street, Suite 101,
New Haven, CT 06511
Phone: 475-210-0212
Email: info@haldathera.com
